2025 has been industry-defining for the genome editing space. With baby KJ successfully receiving the world's first personalized CRISPR therapy, alongside continued innovation across in vivo and base editing, and rapid ex vivo clinical progress, the field stands at a pivotal juncture, ready to unlock the transformative potential of both established assets, and cutting-edge breakthroughs.